OCT tops the list of the leading CROs in Q3 2017. To date, OCT has successfully completed more than 250 clinical projects.
In 2016, our clinical trial portfolio has seen a two-fold increase. A wide network of study sites and well-refined project management methodologies allow OCT to retain its stably leading position of the most reliable and experienced CRO in Eastern Europ
More than 200 clinical trials completed. Successfully passed over 40 audits by leading pharmaceutical companies. OCT has 80 long-standing strategic partners. The team now counts 200 people.
After reaching the point in its development where it could operate independently, OCT’s data management department spun-off into a separate company — Data MATRIX — with a team of 40 specialists.
OCT conducts clinical trials in eight countries, including in North America. The number of staff reaches 120 employees.
Completion of development of the IWRS — a tool for randomization of subjects and management of blinded drug supplies completed. The total number of employees operating across 6 offices reaches 90 people.
Launch of the in-house EDC platform. Pharmacovigilance added to OCT’s services portfolio. The number of employees reaches 85.
First data management services agreement signed. The number of employees reaches 75.
OCT continues to expand its geographic presence across the CIS and EU. Data management and statistics department established.
New offices in Minsk, Riga and Moscow are opened. Each office is manned by project managers and CRAs. The number of employees reaches 50.
OCT continues to strengthen its market presence by opening local offices in Kiev and Sofia. The number of the company’s personnel doubles.
A team of 10 dedicated specialists starts to provide regulatory and monitoring services in Russia.
First contract for local project management and clinical monitoring in Russia signed.